2024
Underuse of Lifesaving Medications for Opioid Use Disorder in US Jails
Springer S. Underuse of Lifesaving Medications for Opioid Use Disorder in US Jails. JAMA Network Open 2024, 7: e2434649. PMID: 39316405, DOI: 10.1001/jamanetworkopen.2024.34649.Peer-Reviewed Original ResearchConsiderations when prescribing opioid agonist therapies for people living with HIV
Tarfa A, Lier A, Shenoi S, Springer S. Considerations when prescribing opioid agonist therapies for people living with HIV. Expert Review Of Clinical Pharmacology 2024, 17: 549-564. PMID: 38946101, PMCID: PMC11299801, DOI: 10.1080/17512433.2024.2375448.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidAnti-HIV AgentsBuprenorphineDelayed-Action PreparationsDelivery of Health CareDrug InteractionsHealth Services AccessibilityHIV InfectionsHumansMethadoneNaltrexoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPre-Exposure ProphylaxisUnited StatesConceptsOpioid agonist therapyOpioid use disorderAntiretroviral therapyAgonist therapyDiagnosed OUDOpioid use disorder managementUse disorderTreatment of opioid use disorderExtended-release naltrexonePotential drug interactionsOpioid use disorder treatmentPrescribed opioid agonist therapyLong-acting formulationPre-exposure prophylaxisOUD outcomesImprove HIV preventionIntersection of HIVOpioid antagonistHIV outcomesHIV epidemicOpioidHIVOpioid use disorder servicesPWHHIV preventionSerious Opioid Injection-Related Infection and Initiation of Medication for Opioid Use Disorder
Springer S. Serious Opioid Injection-Related Infection and Initiation of Medication for Opioid Use Disorder. JAMA Network Open 2024, 7: e2421640. PMID: 39046746, DOI: 10.1001/jamanetworkopen.2024.21640.Peer-Reviewed Original Research
2023
Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial
Seval N, Nunez J, Roth P, Schade M, Strong M, Frank C, Litwin A, Levin F, Brady K, Nunes E, Springer S. Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial. Journal Of Addiction Medicine 2023, 17: e232-e239. PMID: 37579095, PMCID: PMC10368784, DOI: 10.1097/adm.0000000000001136.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineHumansInpatientsMethadoneOpiate Substitution TreatmentOpioid-Related DisordersPainConceptsOpioid use disorderFull agonist opioidsAgonist opioidsHospital dischargeCase seriesSurgical interventionUse disordersCurrent opioid use disorderInfectious disease physiciansLow-dose strategyMulticenter clinical trialPotential surgical interventionLife-threatening infectionsCOMMIT trialComplex hospitalizationsDepot buprenorphineOpioid relapseUnderused medicationsOpioid withdrawalSublingual buprenorphineBuprenorphine dosesDisease physiciansConcurrent painClinical trialsConcurrent infection
2022
Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder
Lier AJ, Seval N, Vander Wyk B, Di Paola A, Springer SA. Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder. Journal Of Substance Use And Addiction Treatment 2022, 142: 108852. PMID: 35988513, PMCID: PMC9509444, DOI: 10.1016/j.jsat.2022.108852.Peer-Reviewed Original ResearchConceptsInjection opioid useOpioid use disorderHepatitis C virusOpioid useXR-NTXOpioid injectionUse disordersDouble-blind placebo-controlled trialExtended-release naltrexonePlacebo-controlled trialCopies/mLIntravenous opioid useTransmission of HIVJustice-involved populationsJustice-involved participantsInjection equipmentHigh treatment groupJustice-involved personsHCV antibodiesHIV RNAPlacebo groupTreat analysisC virusInjection useJustice-involved individualsGender differences among persons entering medication treatment for opioid use disorder in the community
Di Paola A, Taweh N, Biondi BE, Forray A, Frank CA, Shaw A, Springer SA. Gender differences among persons entering medication treatment for opioid use disorder in the community. American Journal On Addictions 2022, 31: 390-395. PMID: 35652902, PMCID: PMC9463117, DOI: 10.1111/ajad.13304.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineFemaleHumansMaleNaltrexoneOpiate Substitution TreatmentOpioid-Related DisordersQuality of LifeSex FactorsConceptsOpioid use disorderUse disordersQuality of lifeDSM-5 diagnosisPosttraumatic stress disorderOpioid relapseMedication useMedication historyMedication treatmentPsychiatric comorbidityPsychiatric medicationsHigh riskMOUDDepression severityGreater prevalenceGender differencesBaseline assessmentPsychological QoL.Disorder screeningStress disorderMultidisciplinary programGeneralized anxietyWomenMedicationsDisordersStudy protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons
Springer SA, Nijhawan AE, Knight K, Kuo I, Di Paola A, Schlossberg E, Frank CA, Sanchez M, Pankow J, Proffitt RP, Lehman W, Pulitzer Z, Thompson K, Violette S, Harding KK. Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons. BMC Infectious Diseases 2022, 22: 380. PMID: 35428213, PMCID: PMC9013109, DOI: 10.1186/s12879-022-07354-x.Peer-Reviewed Original ResearchConceptsJustice-involved individualsAntiretroviral treatmentHIV preventionUse disordersStudy participantsStimulant useSubstance use disorder servicesCommunity-based HIVPost-release interventionsPrimary implementation outcomeHIV viral loadPre-exposure prophylaxisOpioid use disorderTreatment of HIVHIV risk behaviorsRisk of HIVSubstance use disordersHigh-risk communitiesHybrid type 1Justice-involved personsHCV testingLinkage interventionHIV careSecondary outcomesART adherenceFactors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community
Biondi BE, Vander Wyk B, Schlossberg EF, Shaw A, Springer SA. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community. Addiction Science & Clinical Practice 2022, 17: 15. PMID: 35255967, PMCID: PMC8899775, DOI: 10.1186/s13722-022-00299-1.Peer-Reviewed Original ResearchConceptsOpioid use disorderHigher pain interferenceMOUD retentionPain interferenceUse disordersOngoing prospective cohort studySevere opioid use disorderProspective cohort studyMultivariable logistic regressionCohort of adultsMethadone doseAnalgesic effectBuprenorphine doseCohort studyOpioid useResultsA totalHigher oddsMOUDAdjusted modelHigh doseLogistic regressionBuprenorphineMethadoneDoseDiscontinuation
2021
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)
Waddell EN, Springer SA, Marsch LA, Farabee D, Schwartz RP, Nyaku A, Reeves R, Goldfeld K, McDonald RD, Malone M, Cheng A, Saunders EC, Monico L, Gryczynski J, Bell K, Harding K, Violette S, Groblewski T, Martin W, Talon K, Beckwith N, Suchocki A, Torralva R, Wisdom JP, Lee JD. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS). Journal Of Substance Use And Addiction Treatment 2021, 128: 108389. PMID: 33865691, PMCID: PMC8384640, DOI: 10.1016/j.jsat.2021.108389.Peer-Reviewed Original ResearchConceptsOpioid use disorderSelf-reported opioid useOpioid-positive urine samplesExtended-release buprenorphineExtended-release naltrexoneOpioid overdose eventsXR-NTXOpioid treatmentObservational cohortOpioid useUsual armCare outcomesUse disordersNoninferiority designOverdose eventsUrine samplesBuprenorphineTreatmentAdultsEnhanced treatmentNaltrexoneRCTsCohortU.S. localesTrials
2020
The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons A Systematic Review
Seval N, Wurcel A, Gunderson CG, Grimshaw A, Springer SA. The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons A Systematic Review. Infectious Disease Clinics Of North America 2020, 34: 559-584. PMID: 32782102, PMCID: PMC7437982, DOI: 10.1016/j.idc.2020.06.011.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidHepatitis CHumansIncidenceOpioid-Related DisordersPrevalencePrisonersPrisonsRiskSubstance Abuse, IntravenousAddressing the Intersection of Infectious Disease Epidemics and Opioid and Substance Use Epidemics
Springer SA, del Rio C. Addressing the Intersection of Infectious Disease Epidemics and Opioid and Substance Use Epidemics. Infectious Disease Clinics Of North America 2020, 34: xiii-xiv. PMID: 32782107, PMCID: PMC7414777, DOI: 10.1016/j.idc.2020.06.016.Peer-Reviewed Original ResearchLessons Learned from the Response to the Human Immunodeficiency Virus Epidemic that Can Inform Addressing the Opioid Epidemic
Springer SA, del Rio C. Lessons Learned from the Response to the Human Immunodeficiency Virus Epidemic that Can Inform Addressing the Opioid Epidemic. Infectious Disease Clinics Of North America 2020, 34: 637-647. PMID: 32782106, PMCID: PMC7414693, DOI: 10.1016/j.idc.2020.06.015.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidHIV InfectionsHumansOpioid EpidemicOpioid-Related DisordersUnited StatesA Call to Action to Combat the Opioid Epidemic Among Women.
Springer SA, Biondi BE, Frank C, El-Bassel N. A Call to Action to Combat the Opioid Epidemic Among Women. Journal Of Addiction Medicine 2020, 14: 364-366. PMID: 32011410, PMCID: PMC7392801, DOI: 10.1097/adm.0000000000000622.Peer-Reviewed Original Research
2019
Hepatitis C Virus Reinfection Rate Among Persons Who Use Drugs and Are Maintained on Medication Treatment for Opioid Use Disorder
Springer SA. Hepatitis C Virus Reinfection Rate Among Persons Who Use Drugs and Are Maintained on Medication Treatment for Opioid Use Disorder. Clinical Infectious Diseases 2019, 70: 2703-2705. PMID: 31346595, PMCID: PMC7286379, DOI: 10.1093/cid/ciz695.Peer-Reviewed Original ResearchActions to Integrate Treatment of Opioid and Infectious Disease Epidemics.
Springer SA, Korthuis PT, Del Rio C. Actions to Integrate Treatment of Opioid and Infectious Disease Epidemics. Annals Of Internal Medicine 2019, 170: 509. PMID: 30934074, DOI: 10.7326/l19-0042.Peer-Reviewed Original Research
2016
Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine
Makarenko I, Mazhnaya A, Polonsky M, Marcus R, Bojko MJ, Filippovych S, Springer S, Dvoriak S, Altice FL. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. Drug And Alcohol Dependence 2016, 165: 213-220. PMID: 27370527, PMCID: PMC5094181, DOI: 10.1016/j.drugalcdep.2016.06.011.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentAdjusted odds ratioOpioid use disorderAgonist treatmentUse disordersSignificant adjusted odds ratiosMultivariable logistic regressionHIV-negative statusPatient-level interventionsOpioid-dependent peopleInjection frequencyHIV statusOdds ratioRecent overdoseIndependent factorsPWIDLogistic regressionPrevious imprisonmentHigher injection frequencySignificant correlatesPrior incarcerationFamily supportDisordersDrugsIntervention